证券代码：603538 证券简称：美诺华 公告编号：2021-097 债券代码：113618 债券简称：美诺转债 宁波美诺华药业股份有限公司 关于接待机构投资者调研的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、机构调研情况 调研时间：2021 年 11 月 24 日 调研形式：现场接待 调研地点：宁波美诺华药业股份有限公司 调研机构（排名不分先后）：兴业证券、君合资本、泽源资产、融通基金、 光大保德信、长信基金、广银理财、惠升基金、神农投资、君和资本、中泰证券、 深圳杉树投资 接待人员：董事会秘书：应高峰，投资者关系管理总监：史艳丽，董事会办 公室总经理：姚芳，投资者关系管理经理：温霖炜 二、调研主要内容 （一）近期，国家发展改革委、工业和信息化部出台《推动原料药产业高质 量发展实施方案通知》，国务院反垄断委员会发布《关于原料药领域的反垄断指 南》宁波美诺华药业股份有限公司（以下简称"公司"或"美诺华"）怎么看待 这两个文件的颁布。 答：由《推动原料药产业高质量发展实施方案通知》可见国家对原料药制造 端的重 ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥227,070,437.93, a decrease of 23.73% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was ¥19,040,437.69, reflecting a decline of 45.84% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥16,408,956.10, down 47.65% from the previous year[5]. - The net profit for Q3 2021 was CNY 147,629,427.21, a decrease of 2.1% compared to CNY 151,263,113.19 in Q3 2020[21]. - The operating profit for Q3 2021 was CNY 168,916,010.91, down from CNY 183,313,143.88 in the same period last year, reflecting a decline of 7.6%[20]. - The total comprehensive income for Q3 2021 was CNY 147,764,009.20, slightly lower than CNY 150,824,173.02 in Q3 2020[21]. - The diluted earnings per share for Q3 2021 was CNY 0.87, down from CNY 0.96 in Q3 2020, representing a decrease of 9.4%[22]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥184,056,771.80, a decrease of 19.46% compared to the same period last year[5]. - The cash flow from operating activities for the first nine months of 2021 was CNY 184,056,771.80, down 19.5% from CNY 228,532,174.90 in the previous year[23]. - The company reported a net cash outflow from investing activities of CNY 573,601,552.12 for the first nine months of 2021, compared to a net outflow of CNY 276,977,525.68 in the same period of 2020[24]. - The company’s cash and cash equivalents at the end of Q3 2021 amounted to CNY 248,711,439.05, an increase from CNY 243,752,877.70 at the end of Q3 2020[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,725,683,750.51, an increase of 18.34% from the end of the previous year[5]. - Current assets as of September 30, 2021, totaled RMB 1,608,032,587.97, an increase from RMB 1,199,262,158.26 at the end of 2020, reflecting a growth of 34.1%[15]. - Non-current assets increased to RMB 2,117,651,162.54 as of September 30, 2021, compared to RMB 1,949,016,531.82 at the end of 2020, representing a growth of 8.7%[16]. - Total liabilities amounted to RMB 1,669,932,767.08, compared to RMB 1,355,296,200.86 at the end of 2020, indicating an increase of 23.2%[17]. - The company's equity attributable to shareholders was RMB 1,831,996,255.63, up from RMB 1,582,222,330.35 at the end of 2020, reflecting a growth of 15.7%[17]. Research and Development - The company increased R&D expenses by ¥10,930,000, a year-on-year increase of 82.97%[10]. - Research and development expenses increased to CNY 50,073,150.42, up 41.7% from CNY 35,332,495.30 in Q3 2020[20]. Revenue and Costs - Total operating revenue for the first three quarters of 2021 was RMB 918,703,339.02, a decrease of 3.2% compared to RMB 948,915,031.53 in the same period of 2020[19]. - Total operating costs for the first three quarters of 2021 were RMB 780,731,585.79, down from RMB 785,657,488.60 in the previous year, indicating a slight reduction of 0.3%[19]. - The total revenue from operating activities for the first nine months of 2021 was CNY 838,036,257.86, a decrease of 11.5% compared to CNY 946,483,391.70 in the same period of 2020[23]. Government Support - The company received government subsidies amounting to ¥4,516,394.53 during the reporting period, contributing to its financial performance[9]. - The company acquired Ningbo High-tech Zone Meinuo Pharmaceutical Innovation Research Institute, impacting the consolidated financial statements[6].

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was RMB 100 million, up 20% compared to the same period last year[15]. - The company's operating revenue for the first half of 2021 was ¥691,632,901.09, representing a 6.21% increase compared to the same period last year[22]. - Net profit attributable to shareholders was ¥116,351,001.63, reflecting a 9.84% increase year-over-year[22]. - The company achieved total revenue of 692 million yuan, a year-on-year increase of 6.21%[60]. - Net profit attributable to shareholders reached 116 million yuan, up 9.84% year-on-year[60]. - The company reported a total guarantee amount of 76,000,000 RMB, which accounts for 42.24% of the company's net assets[134]. Research and Development - The R&D expenditure for the first half of 2021 was RMB 50 million, accounting for 10% of total revenue[15]. - The R&D team consists of 374 personnel in API development and 79 in formulation development, with over 17% holding master's or doctoral degrees[55]. - Research and development expenses increased to CNY 25,964,245.54, up from CNY 22,155,929.92, indicating a focus on innovation[169]. - The company is committed to continuous R&D investment and the recruitment of talented personnel to improve the success rate of R&D projects[101]. Market Expansion and Strategy - The company has expanded its user base by 10%, reaching a total of 1 million active users[15]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[15]. - The company aims to achieve a revenue growth target of 25% for the full year 2021[15]. - The company is exploring potential mergers and acquisitions to enhance its market presence in Southeast Asia[15]. - The company has established a new partnership with a leading pharmaceutical firm to co-develop new therapies[15]. - The company has implemented a new marketing strategy that is expected to increase market penetration by 15%[15]. - The company is focusing on expanding its CDMO business, which is showing rapid growth and is a key strategic direction[30]. - The company aims to enhance its integrated service platform for CDMO, providing comprehensive R&D and production services for pharmaceutical companies[35]. - The company is actively developing its formulation business, with a focus on chronic disease treatment products, leveraging its existing raw material drugs[36]. - The company is expanding its product categories and exploring new therapeutic areas, including endocrine, antiviral, and anti-infection, while strengthening collaborations with strategic customers[38]. Financial Position and Assets - The company's total assets increased by 14.85% to ¥3,615,945,990.62 compared to the end of the previous year[22]. - The company's cash and cash equivalents at the end of the period were 283.12 million yuan, representing 7.81% of total assets, an increase of 19.70% from the previous year[84]. - The company's total assets increased from approximately 3.15 billion RMB at the beginning of the period to approximately 3.62 billion RMB at the end of the period, reflecting a growth of about 14.8%[158]. - The company's total liabilities increased from approximately 1.36 billion RMB to approximately 1.60 billion RMB, resulting in a debt-to-asset ratio increase from 43.05% to 44.12%[158]. Environmental and Safety Management - The company has established a high-standard EHS management system, continuously improving production automation and safety standards[51]. - The company has established an EHS management system based on international standards to mitigate safety and environmental risks associated with its production processes[99]. - The company has implemented measures to enhance pollution control and environmental management at its non-key pollutant units, ensuring stable wastewater treatment capacity[124]. - The company has installed online monitoring devices at wastewater and air emission outlets to ensure real-time monitoring of pollutant discharge concentrations and total wastewater discharge[122]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the report[15]. - The company faces market competition risks in the raw material pharmaceutical business due to capacity certification cycles and technology transfer, which may affect the pace of capacity release[100]. - The company has a high overseas market revenue proportion, and fluctuations in exchange rates can directly impact profitability, prompting the company to implement measures such as forward exchange rate hedging[100]. Shareholder and Corporate Governance - The company has committed to linking executive compensation to the execution of immediate return measures[127]. - The company guarantees to avoid any direct or indirect competition with its subsidiaries, ensuring no similar business activities[127]. - The company has pledged to comply with the company's articles of association and not seek undue benefits through its controlling position[127]. - The company will ensure that any business activities that may compete with its subsidiaries will be promptly transferred or terminated if identified[127]. - The company has established a legal commitment to uphold shareholder rights and will bear legal responsibility for any violations causing losses[127]. Investment and Financing - The company issued 5.2 million convertible bonds with a total value of RMB 520 million, which began trading on February 4, 2021[151]. - The interest rates for the convertible bonds are set to increase from 0.4% in the first year to 2.0% in the sixth year[151]. - The conversion period for the bonds is from July 20, 2021, to January 13, 2027[151]. - The company reported a net cash flow from investing activities of -¥458,759,705.86, worsening from -¥198,676,380.45 in the first half of 2020[175]. Compliance and Legal Matters - The company had no major litigation or arbitration matters during the reporting period[130]. - The company’s management emphasized the importance of compliance after a senior executive received a warning for short-term trading of company stock[129]. - The company has completed compliance approval for four environmental projects during the reporting period[119].

Financial Performance - Net profit attributable to shareholders rose by 15.43% to CNY 50,345,263.70 year-on-year[8] - Operating revenue grew by 18.55% to CNY 338,290,234.90 compared to the same period last year[8] - Basic earnings per share increased by 13.33% to CNY 0.34[8] - Operating profit for Q1 2021 was ¥62,682,715.24, up from ¥54,940,340.74 in Q1 2020, reflecting a growth of 14.3%[27] - Net profit for Q1 2021 amounted to ¥53,845,524.75, representing a 15.5% increase from ¥46,423,494.57 in Q1 2020[27] - The gross profit margin for Q1 2021 was approximately 34.9%, compared to 35.1% in Q1 2020, showing a slight decrease[26] Assets and Liabilities - Total assets increased by 15.72% to CNY 3,643,086,004.71 compared to the end of the previous year[8] - Current assets totaled CNY 1,658,067,521.29, up from CNY 1,199,262,158.26 at the end of 2020, indicating a growth of about 38.3%[19] - Total liabilities reached CNY 1,700,820,071.93, compared to CNY 1,355,296,200.86 at the end of 2020, representing an increase of approximately 25.5%[20] - Long-term borrowings increased to CNY 196,506,970.87 from CNY 108,506,970.87, reflecting an increase of approximately 81%[20] - The company's equity attributable to shareholders rose to CNY 1,727,813,396.50 from CNY 1,582,222,330.35, indicating a growth of about 9.2%[21] Cash Flow - The net cash flow from operating activities decreased by 118.23% to -CNY 18,738,767.96[8] - The net cash flow from operating activities for Q1 2021 was negative at approximately -¥18.74 million, compared to positive cash flow of ¥102.81 million in Q1 2020[33] - Cash inflow from investment activities in Q1 2021 was approximately ¥152.33 million, while cash outflow was approximately ¥667.39 million, resulting in a net cash flow of -¥515.06 million[33] - Cash inflow from financing activities for Q1 2021 was approximately ¥859.84 million, with a net cash flow of ¥564.78 million after outflows[33] Investments and Acquisitions - The company completed the acquisition of 100% equity in Ningbo High-tech Zone Meinuohua Pharmaceutical Innovation Research Institute for CNY 47,104,000[14] - The company issued convertible bonds totaling CNY 520,000,000, with a net amount of CNY 512,697,629.67 after expenses[13] Shareholder Information - The total number of shareholders reached 21,742 by the end of the reporting period[12] Research and Development - Research and development expenses increased to ¥13,210,864.94 in Q1 2021, up 62.5% from ¥8,146,385.57 in Q1 2020[26] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27]

Financial Performance - In 2020, the net profit attributable to shareholders was approximately ¥167.37 million, while the net profit of the parent company was about ¥73.49 million[8]. - The company's operating revenue for 2020 was approximately CNY 1.19 billion, a slight increase of 1.14% compared to 2019, with a compound annual growth rate of 12.03%[27]. - The net profit attributable to shareholders for 2020 was CNY 167.37 million, representing a year-on-year increase of 10.91%[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 80.53 million, a significant decrease of 42.59% compared to the previous year, primarily due to impairment provisions[27]. - The net cash flow from operating activities for the year was CNY 251.61 million, reflecting good sales cash recovery and extended payment cycles for suppliers[28]. - The company's total assets at the end of 2020 were approximately CNY 3.06 billion, an increase of 17.17% from the previous year[25]. - The net assets attributable to shareholders at the end of 2020 were approximately CNY 1.55 billion, up 13.75% year-on-year[25]. - The basic earnings per share for 2020 were CNY 1.14, an increase of 9.62% compared to 2019[26]. - The diluted earnings per share for 2020 were CNY 1.13, reflecting a 9.71% increase from the previous year[26]. - The company experienced a 70.52% decrease in revenue from its pharmaceutical distribution business, amounting to a reduction of CNY 98.45 million[27]. - The company reported a total non-operating income of RMB 86,839,657.62 in 2020, a significant increase compared to RMB 10,625,893.66 in 2019[31]. - The fair value changes of trading financial assets resulted in a profit of RMB 100,356,005.82, primarily from the appreciation of a 13.5% stake in Zhejiang Huishi Pharmaceutical valued at RMB 85,129,369.41[31]. Production and Capacity Expansion - The company is expanding production capacity with projects including 1,600 tons of raw materials in Xuancheng and 30 billion solid preparations annually in TianKang[5]. - The company’s production capacity includes a total of 2,200 m³ of cGMP-compliant reaction vessels, supporting a wide range of chemical reactions[51]. - The production capacity utilization rate of the Xuancheng Meinuohua facility has gradually increased to over 40%, with expectations to exceed 60% in 2021[64]. - The company completed the construction of its "annual production of 30 billion solid formulations" project, which is expected to finish equipment installation by December 2021[75]. - The company is accelerating the construction of API production capacity, with projects in Zhejiang and Anhui expected to be operational within 2-3 years, ensuring sustainable development and supporting global business expansion[143]. Research and Development - The company has a robust R&D team with 374 personnel in API development and 79 in formulation development, with over 17% holding master's or doctoral degrees[54]. - The company’s total R&D investment reached ¥80,589,624.05, accounting for 6.75% of total revenue, with a year-on-year growth of 28.44%[93][94][110]. - The company submitted 12 patent applications and received 13 patents during the reporting period, enhancing its innovation capabilities[110]. - The company has ongoing R&D projects, including apixaban and sitagliptin, which are currently under CDE review[113]. - R&D expenses increased by 17.16% to CNY 62.05 million, driven by higher investment in R&D projects and improved compensation for R&D personnel[80]. - The company’s R&D investment in formulation projects was significant, with project 2 receiving 843.28 million RMB, accounting for 0.71% of operating income[120]. Market Position and Strategy - The company has established long-term stable partnerships with internationally renowned pharmaceutical companies, enhancing its brand recognition and competitive advantage[5]. - The company operates in high-growth therapeutic areas, including cardiovascular, central nervous system, respiratory, oncology, anti-infection, and digestive systems[4]. - The company aims to enhance its product pipeline in the chronic disease treatment area, focusing on hypertension, hyperlipidemia, and diabetes[40]. - The global market share for the company's sartans products is nearly 20%, while the market share for the perindopril series exceeds 60%, and for rosuvastatin series products, it is close to 50%[52][53]. - The company plans to leverage its existing production capacity to expand its product offerings in endocrine, antiviral, and anti-infection therapeutic areas[41]. - The company is focused on establishing a comprehensive CDMO service platform, enhancing its technical capabilities and project management processes to increase customer retention[144]. Environmental and Social Responsibility - The company was rated as "Excellent" in the corporate social responsibility assessment in Ningbo City in April 2020[190]. - During the pandemic, the company donated 2,000 masks and provided 1 ton of 75% ethanol disinfectant for free to local enterprises[190]. - The company implemented a wastewater treatment system with a new aerobic pool and iron-carbon Fenton system, which is currently operating normally[195]. - The actual wastewater discharge for COD was 27.76 tons, significantly lower than the approved limit of 54.85 tons[192]. - The company processed 3,317 tons of solid waste in 2020, with no exceedances reported[192]. - The company has installed online monitoring devices at wastewater and air discharge points to ensure real-time monitoring of pollutant concentrations[198]. Dividend and Profit Distribution - The company has revised its profit distribution policy to align with regulatory requirements and support future development[151]. - The company plans to distribute a cash dividend of 1.1 RMB per 10 shares, totaling 16,465,020 RMB, which represents 10.91% of the net profit attributable to shareholders for 2019[156]. - The company has not proposed a cash dividend distribution for the reporting period, citing significant investments in project development and operations as the reason for retaining profits[160]. - The company’s cash dividend policy stipulates that in the absence of special circumstances, at least 30% of the average distributable profit over the last three years should be distributed as cash dividends[156]. - The company’s cash dividend distribution for 2018 was 2.00 RMB per 10 shares, totaling 2,981.12 million RMB, which was 30.94% of the net profit[158]. Compliance and Governance - The company appointed Lixin Accounting Firm as the auditor for the fiscal year 2020, with an audit fee of RMB 750,000[168]. - The company has not reported any instances of fund occupation or overdue receivables during the reporting period[166]. - The company guarantees strict compliance with the company's articles of association and will not seek improper benefits through its controlling shareholder status[164]. - The company has committed to maintaining the legal rights of all shareholders and will not harm their interests[164]. - The company will ensure that any unavoidable related party transactions are conducted at fair market prices and comply with disclosure obligations[162].

Financial Performance - Operating income for the first nine months reached CNY 948,233,712.32, an increase of 11.37% year-on-year[6]. - Net profit attributable to shareholders increased by 10.21% to CNY 141,025,306.99 compared to the same period last year[6]. - The company achieved operating revenue of CNY 948.23 million in Q3 2020, an increase of CNY 96.83 million or 11.37% year-over-year[14]. - Total operating revenue for the first three quarters of 2020 reached approximately ¥948 million, an increase of 11.4% from ¥851 million in the same period of 2019[28]. - The total operating income for the first nine months of 2020 was 1,079,941,891.61 CNY, up from 932,089,623.55 CNY in the same period of 2019, representing an increase of approximately 15.9%[35]. - The company reported a total profit of -3,497,634.10 CNY for Q3 2020, compared to a profit of 44,425,632.92 CNY in Q3 2019, highlighting a drastic decline in profitability[33]. Cash Flow - The net cash flow from operating activities surged by 102.73% to CNY 224,146,747.56 for the first nine months[6]. - Net cash flow from operating activities was CNY 224.15 million, a significant increase of 102.73% compared to the previous year[15]. - The net cash flow from operating activities for the first nine months of 2020 was 224,146,747.56 CNY, compared to 110,564,673.93 CNY in the same period of 2019, showing a growth of about 102.3%[35]. - In Q3 2020, the net cash flow from operating activities was ¥91,159,035.22, an increase of 55.8% compared to ¥58,529,654.13 in Q3 2019[39]. - The cash flow from investment activities for the first nine months of 2020 was -279,783,009.29 CNY, worsening from -71,813,809.82 CNY in the same period of 2019[36]. - The total cash outflow from investing activities was ¥301,071,520.99, resulting in a net cash flow from investing activities of -¥248,734,997.82, compared to a positive cash flow of ¥130,562,888.17 in the previous year[39]. Assets and Liabilities - Total assets increased by 8.23% year-on-year to CNY 2,829,210,269.75[6]. - Total liabilities increased to CNY 1,092,630,469.06, up from CNY 1,045,449,722.31, representing a growth of approximately 4.5% year-over-year[22]. - Current assets totaled CNY 547,556,620.90, an increase from CNY 493,932,755.78, marking a growth of approximately 10.9%[25]. - Long-term equity investments increased to CNY 1,227,556,916.73 from CNY 1,031,678,436.57, showing a growth of about 19%[25]. - The total assets as of Q3 2020 were ¥2,613,969,520.44, with total liabilities of ¥1,045,449,722.31, resulting in total equity of ¥1,568,519,798.13[44]. - Total liabilities stood at RMB 877,219,341.20, reflecting the company's leverage[48]. Shareholder Information - Net assets attributable to shareholders rose by 11.53% to CNY 1,521,450,797.63 compared to the end of the previous year[6]. - The total number of shareholders reached 17,287 by the end of the reporting period[10]. - The largest shareholder, Ningbo Meinuohua Holdings Co., Ltd., holds 21.66% of the shares[10]. Profitability Metrics - Basic earnings per share rose by 8.99% to CNY 0.97, while diluted earnings per share increased by 12.94% to CNY 0.96[6]. - The weighted average return on equity decreased by 0.42 percentage points to 9.82%[6]. - The company reported a net profit margin improvement, with retained earnings increasing to CNY 792,840,590.13 from CNY 668,271,299.15, a rise of approximately 18.7%[22]. - The company incurred credit impairment losses of 3,326,716.87 CNY in Q3 2020, compared to a loss of 823,533.70 CNY in the same period of 2019, indicating a significant increase in credit risk[33]. Research and Development - Research and development expenses increased to CNY 35.18 million, a rise of 9.37% year-over-year, reflecting the company's commitment to innovation[16]. - Research and development expenses for Q3 2020 were approximately ¥13 million, an increase of 7.7% compared to ¥12 million in Q3 2019[28]. Financial Management - Operating costs for the period were CNY 589.67 million, reflecting a year-over-year increase of 10.62%[15]. - The company's gross profit margin remained stable at 37.81%, indicating effective management of production stability and material supply[14]. - Financial expenses surged by 49.37% to CNY 21.74 million, largely due to fluctuations in the USD/CNY exchange rate[16].

Financial Performance - The company's operating revenue for the first half of 2020 was ¥651,211,389.54, representing a 16.01% increase compared to ¥561,336,723.74 in the same period last year [23]. - The net profit attributable to shareholders for the same period was ¥107,493,159.40, which is a 24.57% increase from ¥86,294,151.06 year-on-year [23]. - The basic earnings per share rose to ¥0.74, a 23.33% increase from ¥0.60 in the same period last year [24]. - The weighted average return on equity improved to 7.55%, up from 6.98% year-on-year [24]. - The gross profit margin improved to 38.39%, up by 2.01 percentage points year-on-year, due to enhanced production efficiency and optimized procurement strategies [52]. - The total revenue for the first half of 2020 reached CNY 651,211,389.54, an increase of 15.98% compared to CNY 561,336,723.74 in the first half of 2019 [126]. - The total profit for the first half of 2020 was CNY 136,800,075.91, which is a 21.7% increase from CNY 112,446,501.55 in the same period last year [127]. - The total comprehensive income for the first half of 2020 was CNY 114,645,414.25, compared to CNY 93,826,815.74 in the same period of 2019, reflecting a growth of 22.1% [127]. Assets and Liabilities - The company's total assets increased by 7.19% to ¥2,801,982,466.53 compared to ¥2,613,969,520.44 at the end of the previous year [23]. - The company's total liabilities increased to CNY 1,115,271,018.62 from CNY 1,045,449,722.31, which is an increase of approximately 6.7% [121]. - The company's equity attributable to shareholders rose to CNY 1,474,171,442.10 from CNY 1,364,142,101.27, reflecting an increase of about 8.1% [121]. - The company's retained earnings reached CNY 759,299,438.55, compared to CNY 668,271,299.15, marking an increase of approximately 13.7% [121]. - The company's short-term borrowings increased to CNY 587,705,572.00 from CNY 429,442,625.27, representing a rise of about 36.8% [121]. Cash Flow - The net cash flow from operating activities decreased by 8.79% to ¥124,695,514.98 from ¥136,718,869.45 in the previous year [23]. - The cash flow from operating activities was CNY 610,802,454.68, a decrease from CNY 652,424,193.82 in the previous year [132]. - Cash inflow from financing activities was CNY 644,228,290.05, significantly higher than CNY 250,978,621.71 in the same period last year, marking an increase of 156.5% [134]. - The ending balance of cash and cash equivalents was CNY 243,753,341.13, down from CNY 274,049,338.33 year-on-year [134]. Business Operations - The main business remains focused on the research, production, and sales of pharmaceutical intermediates and specialty APIs, with no significant changes in the business model [29]. - The company operates under a Make To Order (MTO) production model, which allows for flexibility in responding to customer orders while minimizing inventory [30]. - The sales of self-produced products accounted for approximately 89.42% of total sales, indicating a strong focus on proprietary product lines [30]. - The company achieved a 144% year-on-year increase in production capacity utilization for its formulation production line [34]. - The company expanded its product structure to include important therapeutic areas such as antiviral, rheumatology, and oncology, driven by new capacity and new customer entries [33]. Research and Development - The company has a research and development team of 362 personnel, including 61 with master's or doctoral degrees, and has accumulated 107 domestic authorized patents [42]. - The company continues to invest in R&D and recruit talented personnel to improve the success rate of R&D projects [68]. - The company is actively exploring the oncology field for new product development while maintaining a strong presence in cardiovascular and central nervous system treatment areas [46]. Risks and Compliance - The company faces risks related to product quality control, emphasizing the importance of quality management in the production of raw materials [66]. - The company is also exposed to safety production and environmental risks due to the nature of its operations involving hazardous materials [66]. - The company has established an EHS management system based on international standards across all production bases, focusing on safety and environmental protection investments [67]. - The company faces market competition risks due to the involvement of domestic and international competitors in the raw material pharmaceutical business, which may affect capacity release [67]. Shareholder Information - The largest shareholder, Ningbo Meinuohua Holdings Co., Ltd., holds 39,900,000 shares, representing 26.66% of the total shares [109]. - The second-largest shareholder, Yao Chengzhi, holds 8,640,000 shares, accounting for 5.77% of the total shares [109]. - The company has a total of 10 major shareholders, with the top ten holding a combined total of 58,000,000 shares [110]. - The report indicates that there are no strategic investors or general legal entities that have become major shareholders through the placement of new shares [113]. Environmental Management - The actual wastewater discharge for the first half of 2020 was 72,828 tons, with a chemical oxygen demand concentration of 185.16 mg/L, well below the regulatory limit of 500 mg/L [92]. - The actual discharge of volatile organic compounds (VOCs) in waste gas was 5.96 tons, significantly lower than the permitted level of 18.60 tons [92]. - The company reported no major environmental accidents during the reporting period, indicating stable and effective environmental management [100]. - The company has implemented a comprehensive environmental risk emergency mechanism, ensuring efficient response to potential pollution incidents [97]. Strategic Partnerships - The company’s strategic partnership with KRKA has led to deep collaboration in formulation business, optimizing industrial resources [34]. - The company and KRKA jointly increased capital in the subsidiary Kelkang Meinuohua by a total of RMB 300 million, with the company contributing RMB 120 million [58]. - The registered capital of the joint venture established with KRKA is RMB 530 million after the capital increase, with the company holding a 40% stake [59].

Financial Performance - The company's operating revenue for 2019 was CNY 1,180,205,325.50, representing a year-on-year increase of 39.02%[21]. - The net profit attributable to shareholders for 2019 was CNY 150,904,871.05, reflecting a growth of 56.62% compared to the previous year[21]. - The cash flow from operating activities for 2019 was CNY 179,751,928.51, an increase of 285.77% year-on-year[21]. - The basic earnings per share for 2019 was CNY 1.04, up 55.22% from CNY 0.67 in 2018[22]. - The company achieved a compound annual growth rate (CAGR) of 24.93% in operating revenue over the past three years[23]. - The net profit after deducting non-recurring gains and losses increased by 134.53% year-on-year, with a CAGR of 60.87%[23]. - Total assets at the end of 2019 were CNY 2,613,969,520.44, a 15.10% increase from the previous year[21]. - The weighted average return on equity for 2019 was 11.87%, an increase of 3.52 percentage points from 2018[23]. - The company's gross profit margin improved to 38.35%, an increase of 5.78 percentage points year-on-year, driven by enhanced competitiveness in the raw material drug market[60]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 1.10 yuan per 10 shares, totaling approximately 16,465,020 yuan, which represents a cash dividend payout ratio of 10.91% of the net profit attributable to shareholders[5]. - The cash dividend for 2018 was set at 2.00 RMB per 10 shares, totaling 29,826,800 RMB, which is 30.96% of the net profit attributable to shareholders[136]. - The total number of ordinary shares increased from 149,134,000 to 149,682,000, reflecting a net increase of 548,000 shares[186]. - The company’s stock structure includes 58,202,800 restricted shares, accounting for 38.88% of total shares after adjustments[186]. - The company’s total number of unrestricted circulating shares increased to 91,479,200, representing 61.12% of total shares[186]. - The total number of common stock shareholders at the end of the reporting period was 14,254, an increase from 12,605 at the end of the previous month[193]. Risk Management and Compliance - The report includes a detailed description of potential risks that the company may face, emphasizing the importance of investor awareness regarding these risks[7]. - The company has a comprehensive risk management strategy outlined in the report, detailing various operational risks[7]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[7]. - The company has not provided any guarantees in violation of regulatory decision-making procedures, maintaining compliance with legal standards[7]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute commitments to investors, highlighting the associated investment risks[6]. - The company has committed to not occupy its own funds or assets and to avoid abusing the rights of controlling shareholders[143]. - The company will not engage in any business that competes with its subsidiaries, ensuring no direct or indirect competition[144]. Research and Development - The company has over 2,000 specialized personnel in R&D, production, quality, and EHS management for APIs[45]. - The company has a total of 371 R&D personnel, with 103 domestic authorized patents, enhancing its R&D capabilities[47]. - The company invested a total of 6,274.51 million RMB in R&D during the reporting period, accounting for 5.32% of operating revenue[101]. - The company’s R&D investment growth is aligned with operating revenue and net asset conditions, maintaining a mid-range level compared to industry peers[101]. - The company has established three raw material drug R&D institutions and two formulation R&D centers, employing a total of 371 R&D personnel, including 9 PhDs and 53 Masters[97]. - The company is focusing on optimizing resource allocation and promoting green production technologies in response to new environmental regulations[90]. Production and Market Position - The company primarily engages in the research, production, and sales of pharmaceutical intermediates, specialty active pharmaceutical ingredients (APIs), and formulations, with a focus on cardiovascular, central nervous system, and gastrointestinal therapeutic areas[31]. - The company achieved a global market share of approximately 15% for its main sartans, over 30% in Europe, and around 40% for perindopril, with European market share nearing 80%[35]. - The new API production facility in Xuancheng, with a capacity of 1,600 tons, has been successfully launched, enhancing the company's production stability and growth potential[36]. - The company’s formulation business is expected to experience high growth, supported by increased production capacity and a focus on chronic disease treatment combinations[37]. - The company is actively expanding its customer base, including major pharmaceutical companies in China, Russia, and Iran, with over 30 projects in the verification production phase[36]. Environmental and Social Responsibility - The company emphasizes its commitment to environmental protection, with a total solid waste disposal of 1,186.34 tons in 2019[176]. - The company has implemented a new wastewater treatment facility with a capacity of 3.5m³/h, which is currently operating normally[177]. - The company has installed a new air pollution control system with a capacity of 25,000m³/h, which has been successfully commissioned[177]. - The company strictly adheres to environmental regulations, with no instances of exceeding discharge limits reported in 2019[178]. - The company has actively engaged in social responsibility initiatives, focusing on employee welfare and environmental sustainability[172]. Investment and Financial Management - The company has invested 63,000,000 RMB in bank wealth management products using idle raised funds, with an outstanding balance of 13,000,000 RMB[164]. - The company reported a total of 5,000 million in funds raised through various financial products, achieving an average annualized return of 4.00% to 5.00% across different investment vehicles[167]. - The company has successfully redeemed 52.05 million from a structured interest rate swap, indicating effective management of idle funds[167]. - The company is exploring new investment strategies to enhance returns while managing risk exposure in the current market environment[168]. - The company has a strong focus on maintaining liquidity and managing risks associated with its investment portfolio[168]. Strategic Partnerships and Collaborations - The company has formed strategic partnerships with international pharmaceutical companies, including a long-term collaboration with KRKA[48]. - The company has established a joint venture with strategic partner KRKA, resulting in the verification and commercialization of 9 formulation products, with 3 additional products entering the priority review channel in China[37]. - The company completed the transfer of 6 formulation technology varieties and achieved 9 customized production services in Europe[54].

2020 年第一季度报告 公司代码：603538 公司简称：美诺华 宁波美诺华药业股份有限公司 2020 年第一季度报告 1 / 24 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2020 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元 币种：人民币 | | | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | | | | 减(%) | | | 总资产 | 2,792,331,802.42 | 2,613,969,520.44 | 6.82 | | | 归属于上市公司 | 1,408,017,293.08 | 1,364,142,101.27 | 3.22 | | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | 96,708,027.30 | 82,214,775.64 ...

宁波美诺华药业股份有限公司 2019 年第三季度报告 1 / 29 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 11 | 2019 年第三季度报告 2019 年第三季度报告 公司代码：603538 公司简称：美诺华 | | 本报告期末 | 上年度末 | 本报告期末比上年 | | | --- | --- | --- | --- | --- | | | | | 度末增减(%) | | | 总资产 | 2,521,338,113.21 | 2,271,082,082.60 | 11.02 | | | 归属于上市公司股东的净资产 | 1,299,665,106.12 | 1,197,153,948.60 | 8.56 | | | | 年初至报告期末 | 上年初至上年报告 | 比上年同期增减 | | | | （1-9 月） | 期末（1-9 月） | (%) | | | 经营活动产生的现金流量净额 | 110,564,673.93 | 15,798,007.9 ...